What is uFraction8?
Founded in 2017 and headquartered in Falkirk, Scotland, uFraction8 is at the forefront of developing advanced microfluidics-based filtration systems. The company's proprietary technology harnesses hydrodynamic phenomena to offer an energy-efficient and scalable alternative to conventional filtration methods, including filters, membranes, flocculants, and centrifuges. This innovation is particularly impactful for the food, biopharmaceutical, and bio-based product industries, aiming to optimize downstream processing and reduce operational expenditures. uFraction8's technology addresses a critical need for more sustainable and cost-effective bioprocessing solutions.
How much funding has uFraction8 raised?
uFraction8 has raised a total of $7.7M across 2 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$4.3M
Other Financing Round (2022): $3.4M, investors not publicly disclosed
Other Financing Round (2025): $4.3M led by The University of Edinburgh, Old College Capital, Scottish Enterprise, Thia Ventures, Foresight Group, and Alwyn Capital
Key Investors in uFraction8
The University of Edinburgh
The University of Edinburgh is a globally recognized institution known for its research excellence, particularly in scientific and medical fields. Its involvement suggests a strong academic foundation and potential for technology transfer.
Old College Capital
Old College Capital is the venture investment arm of the University of Edinburgh, focusing on early-stage businesses linked to the university. Their participation indicates support for university-originated innovation.
Thia Ventures
Thia Ventures is a fund management company specializing in investments at the intersection of food, biotechnology, and health, indicating a strategic interest in uFraction8's biomanufacturing applications.
What's next for uFraction8?
With the recent influx of major strategic investment and substantial overall enterprise-level funding, uFraction8 is poised to accelerate its product development and market penetration. The company's focus on enhancing biomanufacturing efficiency through its microfluidics technology aligns with growing industry demands for sustainable and scalable solutions. Future endeavors will likely involve expanding its technological applications across a broader range of bio-based industries and strengthening strategic partnerships to further its market reach. The backing from a mix of academic, venture, and strategic investors suggests a strong validation of uFraction8's innovative approach and its potential for significant impact.
See full uFraction8 company page
